AGC Biologics began its cell therapy process development and clinical manufacturing services on July 1, 2025, at its Yokohama Technical Center in Japan.
AGC Wakasa Chemicals, part of Japanese group AGC, has completed a new large-scale production line at its Kaminaka Plant in Fukui prefecture, Japan, as it expects demand for agrochemicals and pharmaceuticals to grow steadily against a backdrop of population growth and improvement of living standards.
AGC Biologics, a biopharma CDMO, has completed the expansion of its manufacturing capacity at the company’s Cell & Gene Center of Excellence in Milan, Italy.
AGC Pharma Chemicals Europe, part of Japanese conglomerate AGC, is expanding capacity for synthetic pharmaceuticals at its site in Malgrat de Mar, Spain. The CDMO will add a new building that will raise existing capacity by 30% when it starts operating in the first half of 2024.
AGC Biologics is expanding capacities for plasmid DNA (pDNA) and messenger RNA (mRNA) at its site in Heidelberg, Germany. The company said in June that it had agreed to supply pDNA to Pfizer/BioNTech for their RNA-based Covid-19 vaccine, manufacturing the ingredient at Heidelberg.
AGC Biologics, US biopharma CDMO, has signed an agreement to buy a cell and gene therapy manufacturing facility in Longmont, Colorado, from Novartis Gene Therapies. Financial terms were not disclosed.
AGC Biologics has agreed to supply plasmid DNA (pDNA) to Pfizer/BioNTech for their RNA-based Covid-19 vaccine. The biopharma CDMO based in Heidelberg, Germany, will manufacture the vaccine ingredient at its Heidelberg facility.
AGC Biologics, a biopharma CDMO, is planning to expand its cell and gene therapy center of excellence in Milan, Italy, to increase capacities and implement viral vector suspension capabilities. Two more floors will be added to the current suite and additional equipment will be installed on the existing floor. The new facilities are scheduled to go into full operation in 2022.
